Medical management of motility disorders in patients with intestinal failure: A focus on necrotizing enterocolitis, gastroschisis, and intestinal atresia

Bryan J. Dicken, Consolato Sergi, Frederick Rescorla, Francine Breckler, David Sigalet

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background: Intestinal failure (IF) is the dependence upon parenteral nutrition to maintain minimal energy requirements for growth and development. It may occur secondary to a loss of bowel length, disorders of motility, or both. Short bowel syndrome (SBS) is a malabsorptive state resulting from surgical resection, congenital defect, or diseases associated with loss of absorptive surface area. A particularly vexing problem is associated with whole bowel and/or segmental intestinal dysmotility. Motility disorders within the context of SBS and IF may relate to rapid intestinal transit secondary to loss of intestinal length, dysmotility associated with loss or poor antegrade peristalsis, or gastroparesis. Therapy may be classified into medical (prokinetic and antidiarrheal agents) and surgical to deal with the overdistended poorly motile bowel. Methods: We performed a systematic review of the literature pertaining to IF, SBS, and dysmotility in the pediatric population with gastroschisis, necrotizing enterocolitis, and intestinal atresia. In addition to the available treatment options, we have provided a review of the literature and a summary of the available evidence. Conclusion: Despite relatively poor level of evidence regarding the application of promotility and antidiarrheal medications in patients with SBS and IF, these agents continue to be used. Herein, we provide a review of the physiology and pathophysiology of intestinal motility/dysmotility and available strategies for the use of promotility and antidiarrheal agents in patients with IF/SBS.

Original languageEnglish
Pages (from-to)1618-1630
Number of pages13
JournalJournal of Pediatric Surgery
Volume46
Issue number8
DOIs
StatePublished - Aug 2011

Fingerprint

Intestinal Atresia
Gastroschisis
Short Bowel Syndrome
Necrotizing Enterocolitis
Antidiarrheals
Gastroparesis
Peristalsis
Gastrointestinal Motility
Parenteral Nutrition
Growth and Development
Pediatrics
Therapeutics
Population

Keywords

  • Antidiarrheal agents
  • Dysmotility
  • Intestinal failure
  • Promotility agents
  • Short bowel syndrome

ASJC Scopus subject areas

  • Surgery
  • Pediatrics, Perinatology, and Child Health

Cite this

Medical management of motility disorders in patients with intestinal failure : A focus on necrotizing enterocolitis, gastroschisis, and intestinal atresia. / Dicken, Bryan J.; Sergi, Consolato; Rescorla, Frederick; Breckler, Francine; Sigalet, David.

In: Journal of Pediatric Surgery, Vol. 46, No. 8, 08.2011, p. 1618-1630.

Research output: Contribution to journalArticle

@article{2ddb8255d0154c2b98d06ee336729cb8,
title = "Medical management of motility disorders in patients with intestinal failure: A focus on necrotizing enterocolitis, gastroschisis, and intestinal atresia",
abstract = "Background: Intestinal failure (IF) is the dependence upon parenteral nutrition to maintain minimal energy requirements for growth and development. It may occur secondary to a loss of bowel length, disorders of motility, or both. Short bowel syndrome (SBS) is a malabsorptive state resulting from surgical resection, congenital defect, or diseases associated with loss of absorptive surface area. A particularly vexing problem is associated with whole bowel and/or segmental intestinal dysmotility. Motility disorders within the context of SBS and IF may relate to rapid intestinal transit secondary to loss of intestinal length, dysmotility associated with loss or poor antegrade peristalsis, or gastroparesis. Therapy may be classified into medical (prokinetic and antidiarrheal agents) and surgical to deal with the overdistended poorly motile bowel. Methods: We performed a systematic review of the literature pertaining to IF, SBS, and dysmotility in the pediatric population with gastroschisis, necrotizing enterocolitis, and intestinal atresia. In addition to the available treatment options, we have provided a review of the literature and a summary of the available evidence. Conclusion: Despite relatively poor level of evidence regarding the application of promotility and antidiarrheal medications in patients with SBS and IF, these agents continue to be used. Herein, we provide a review of the physiology and pathophysiology of intestinal motility/dysmotility and available strategies for the use of promotility and antidiarrheal agents in patients with IF/SBS.",
keywords = "Antidiarrheal agents, Dysmotility, Intestinal failure, Promotility agents, Short bowel syndrome",
author = "Dicken, {Bryan J.} and Consolato Sergi and Frederick Rescorla and Francine Breckler and David Sigalet",
year = "2011",
month = "8",
doi = "10.1016/j.jpedsurg.2011.04.002",
language = "English",
volume = "46",
pages = "1618--1630",
journal = "Journal of Pediatric Surgery",
issn = "0022-3468",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - Medical management of motility disorders in patients with intestinal failure

T2 - A focus on necrotizing enterocolitis, gastroschisis, and intestinal atresia

AU - Dicken, Bryan J.

AU - Sergi, Consolato

AU - Rescorla, Frederick

AU - Breckler, Francine

AU - Sigalet, David

PY - 2011/8

Y1 - 2011/8

N2 - Background: Intestinal failure (IF) is the dependence upon parenteral nutrition to maintain minimal energy requirements for growth and development. It may occur secondary to a loss of bowel length, disorders of motility, or both. Short bowel syndrome (SBS) is a malabsorptive state resulting from surgical resection, congenital defect, or diseases associated with loss of absorptive surface area. A particularly vexing problem is associated with whole bowel and/or segmental intestinal dysmotility. Motility disorders within the context of SBS and IF may relate to rapid intestinal transit secondary to loss of intestinal length, dysmotility associated with loss or poor antegrade peristalsis, or gastroparesis. Therapy may be classified into medical (prokinetic and antidiarrheal agents) and surgical to deal with the overdistended poorly motile bowel. Methods: We performed a systematic review of the literature pertaining to IF, SBS, and dysmotility in the pediatric population with gastroschisis, necrotizing enterocolitis, and intestinal atresia. In addition to the available treatment options, we have provided a review of the literature and a summary of the available evidence. Conclusion: Despite relatively poor level of evidence regarding the application of promotility and antidiarrheal medications in patients with SBS and IF, these agents continue to be used. Herein, we provide a review of the physiology and pathophysiology of intestinal motility/dysmotility and available strategies for the use of promotility and antidiarrheal agents in patients with IF/SBS.

AB - Background: Intestinal failure (IF) is the dependence upon parenteral nutrition to maintain minimal energy requirements for growth and development. It may occur secondary to a loss of bowel length, disorders of motility, or both. Short bowel syndrome (SBS) is a malabsorptive state resulting from surgical resection, congenital defect, or diseases associated with loss of absorptive surface area. A particularly vexing problem is associated with whole bowel and/or segmental intestinal dysmotility. Motility disorders within the context of SBS and IF may relate to rapid intestinal transit secondary to loss of intestinal length, dysmotility associated with loss or poor antegrade peristalsis, or gastroparesis. Therapy may be classified into medical (prokinetic and antidiarrheal agents) and surgical to deal with the overdistended poorly motile bowel. Methods: We performed a systematic review of the literature pertaining to IF, SBS, and dysmotility in the pediatric population with gastroschisis, necrotizing enterocolitis, and intestinal atresia. In addition to the available treatment options, we have provided a review of the literature and a summary of the available evidence. Conclusion: Despite relatively poor level of evidence regarding the application of promotility and antidiarrheal medications in patients with SBS and IF, these agents continue to be used. Herein, we provide a review of the physiology and pathophysiology of intestinal motility/dysmotility and available strategies for the use of promotility and antidiarrheal agents in patients with IF/SBS.

KW - Antidiarrheal agents

KW - Dysmotility

KW - Intestinal failure

KW - Promotility agents

KW - Short bowel syndrome

UR - http://www.scopus.com/inward/record.url?scp=80051901955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051901955&partnerID=8YFLogxK

U2 - 10.1016/j.jpedsurg.2011.04.002

DO - 10.1016/j.jpedsurg.2011.04.002

M3 - Article

C2 - 21843732

AN - SCOPUS:80051901955

VL - 46

SP - 1618

EP - 1630

JO - Journal of Pediatric Surgery

JF - Journal of Pediatric Surgery

SN - 0022-3468

IS - 8

ER -